Načítá se...
Pasireotide and Octreotide Stimulate Distinct Patterns of sst(2A) Somatostatin Receptor Phosphorylation
Pasireotide (SOM230) is currently under clinical evaluation as a successor compound to octreotide for the treatment of acromegaly, Cushing’s disease, and carcinoid tumors. Whereas octreotide acts primarily via the sst(2A) somatostatin receptor, pasireotide was designed to exhibit octreotide-like sst...
Uloženo v:
| Vydáno v: | Mol Endocrinol |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Endocrine Society
2010
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5428126/ https://ncbi.nlm.nih.gov/pubmed/20051480 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/me.2009-0315 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|